Clinical utility of inflammatory markers and advanced lipoprotein testing: Advice from an expert panel of lipid specialists

Davidson, Michael H., Ballantyne, Christie M., Jacobson, Terry A., Bittner, Vera A., Braun, Lynne T., Brown, Alan S., Brown, W.Virgil, Cromwell, William C. +9 more·2011·Journal of Clinical Lipidology
DOI 10.1016/j.jacl.2011.07.005

Cites (234)

Items 201–234 of 234

  1. Management of Lp(a)
    William Virgil Brown, Christie Mitchell Ballantyne, Peter H. Jones, Santica M. Marcovina · 2010 · Journal of clinical lipidology
  2. Lipoprotein-Associated Phospholipase A2: A Risk Marker or a Risk Factor?
    Amir Lerman, Joseph P. McConnell · 2008 · The American Journal of Cardiology
  3. Assessment of Reaching Goal in Patients with Combined Hyperlipidemia: Low-Density Lipoprotein Cholesterol, Non–High-Density Lipoprotein Cholesterol, or Apolipoprotein B
    Evan A. Stein, Allan D. Sniderman, Peter M. Laskarzewski · 2005 · The American Journal of Cardiology
  4. Screening for Dysbetalipoproteinemia by Plasma Cholesterol and Apolipoprotein B Concentrations
    Dirk Jacobus Blom, F.H. O’Neill, Adrian David Marais · 2005 · Clinical Chemistry
  5. Expression of lipoprotein-associated phospholipase A2 in carotid artery plaques predicts long-term cardiac outcome
    Sandra M. Herrmann, Dallit Mannheim, Claudia Wohlert, Daniele Versari, Fredric Bruce Meyer, Joseph P. McConnell, Mario Gössl, Lilach O. Lerman, Amir Lerman · 2009 · European Heart Journal
  6. Lipoprotein a: where are we now?
    Κωνσταντίνος Τζιόμαλος, Vasilios Gabriel Athyros, Anthony S. Wierzbicki, Dimitri P. Mikhailidis · 2009 · Current Opinion in Cardiology
  7. Clinical Implications of JUPITER (Justification for the Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) in a U.S. Population
    Eric Y. Yang, Vijay Nambi, Zheng-Zheng Tang, Salim S. Virani, Eric Boerwinkle, Ron Cornelis Hoogeveen, Brad C. Astor, Thomas H. Mosley, Josef Coresh, Lloyd E. Chambless et al. · 2009 · Journal of the American College of Cardiology
  8. Underappreciated opportunities for low-density lipoprotein management in patients with cardiometabolic residual risk
    Robert S. Rosenson, Michael H. Davidson, Ray Pourfarzib · 2010 · Atherosclerosis
  9. Effect of age on the association of non-high-density-lipoprotein cholesterol and apolipoprotein B with cardiovascular mortality in a Mediterranean population with type 2 diabetes: the Casale Monferrato study
    Graziella Bruno, Franco Merletti, Annibale Biggeri, Giuseppe Bargero, Stefano Prina Cerai, Gianfranco Pagano, Paolo Cavallo‐Perin · 2006 · Diabetologia
  10. Characterization of lipoprotein in a kindred with familial hypercholesterolemia
    Wolfgang Patsch, Richard E. Ostlund, Ilmar Kuisk, R Levy, Gustav Schonfeld · 1982 · Journal of Lipid Research
  11. Institutional, provider, and patient correlates of low-density lipoprotein and non–high-density lipoprotein cholesterol goal attainment according to the Adult Treatment Panel III guidelines
    Salim S. Virani, LeChauncy Woodard, Cassie R. Landrum, Kenneth Pietz, Degang Wang, Christie Mitchell Ballantyne, Laura A. Petersen · 2011 · American Heart Journal
  12. Intimal and medial plasma protein concentrations and endothelial function
    Elspeth B. Smith, Eileen M. Staples · 1982 · Atherosclerosis
  13. Effects of a low-calorie diet associated with weight loss on lipoprotein-associated phospholipase A2 (Lp-PLA2) activity in healthy obese women
    Themistoklis Tzotzas, Theodosios D. Filippatos, Athanasios A. Triantos, Éric Bruckert, Alexandros D. Tselepis, Dimitrios Nikiforos Kiortsis · 2007 · Nutrition Metabolism and Cardiovascular Diseases
  14. The Johns Hopkins textbook of dyslipidemia
    Peter O. Kwiterovich · 2012
  15. Potential cost-effectiveness of C-reactive protein screening followed by targeted statin therapy for the primary prevention of cardiovascular disease among patients without overt hyperlipidemia
    Blake, Gavin J, Ridker, Paul M, Kuntz, Karen M · 2003 · The American Journal of Medicine
  16. Rosuvastatin for primary prevention in patients with European systematic coronary risk evaluation risk ≥5% or Framingham risk >20%: post hoc analyses of the JUPITER trial requested by European health authorities
    Wolfgang Köenig, Paul M. Ridker · 2010 · European Heart Journal
  17. Opening a New Lipid “Apo-thecary”: Incorporating Apolipoproteins as Potential Risk Factors and Treatment Targets to Reduce Cardiovascular Risk
    Terry A. Jacobson · 2011 · Mayo Clinic Proceedings
  18. Statin therapy reduces inflammatory markers in hypercholesterolemic patients with high baseline levels
    Yuki Horiuchi, Satoshi Hirayama, Satoshi Soda, Utako Seino, Mika Kon, Tsuyoshi Ueno, Mayumi Idei, Osamu Hanyu, Takashi Tsuda, Hirotoshi Ohmura et al. · 2010 · Journal of Atherosclerosis and Thrombosis
  19. LpA-I, LpA-I:A-II HDL and CHD-risk: The Framingham Offspring Study and the Veterans Affairs HDL Intervention Trial
    Bela F. Asztalos, Serkalem Demissie, L. Adrienne Cupples, Dorothea E. Collins, Caitlin E. Cox, Katalin V. Horvath, Hanna E. Bloomfield, Sander J. Robins, Ernst J. Schaefer · 2005 · Atherosclerosis
  20. Factors predicting cardiovascular events in statin-treated diabetic and non-diabetic patients with coronary atherosclerosis
    Heinz Drexel, Stefan Aczél, Thomas Marte, Alexander Vonbank, Christoph H. Saely · 2009 · Atherosclerosis
  21. Lipoprotein‐associated phospholipase A2 activity and mass in relation to vascular disease and nonvascular mortality
    Heart Protection Study Collaborative Group · 2010 · Journal of Internal Medicine
  22. Phospholipase A2 inhibitors
    Hector Garcia-Garcia, Patrick W.J.C. Serruys · 2009 · Current Opinion in Lipidology
  23. Low-density lipoprotein and apolipoprotein B: Clinical use in patients with coronary heart disease
    William C. Cromwell, T. A. Barringer · 2009 · Current Cardiology Reports
  24. HDL proteomics: pot of gold or Pandora’s box?
    Muredach P. Reilly, Alan R. Tall · 2007 · Journal of Clinical Investigation
  25. Lipoprotein-associated phospholipase A(2) activity and mass in relation to vascular disease and nonvascular mortality
    Stanley T. Parish, Alison R. Offer, Alexander G. Thompson · 2010 · Journal of Internal Medicine
  26. Editorial
    Ancel B. Keys · 1961 · Circulation
  27. Lp-PLA2: A New Target for Statin Therapy
    Lynne T. Braun, Michael H. Davidson · 2010 · Current Atherosclerosis Reports
  28. Lipoprotein-associated phospholipase A2: role in atherosclerosis and utility as a cardiovascular biomarker
    Peter Paul Toth, Peter Andrew McCullough, Michael S. Wegner, Kenneth J. Colley · 2010 · Expert Review of Cardiovascular Therapy
  29. High apolipoprotein B with low high-density lipoprotein cholesterol and normal plasma triglycerides and cholesterol
    Allan D. Sniderman, Gilles R. Dagenais, Bernard Cantin · 2001 · The American Journal of Cardiology
  30. Relationship between low-density lipoprotein subclasses and asymptomatic atherosclerosis in subjects from the atherosclerosis risk in communities (ARIC) Study
    D. Michael Hallman, Spencer A. Brown, Christie Mitchell Ballantyne, A. Richey Sharrett, Eric Boerwinkle · 2004 · Biomarkers
  31. Markers in Cardiology
    2007 · Wiley eBooks
  32. Aggressive Lipid-Lowering Therapy and Regression of Coronary Atheroma—Reply
    2004 · JAMA
  33. Lipoprotein Subfraction Analysis Using Nuclear Magnetic Resonance Spectroscopy
    William C. Cromwell, Harold Edward Bays, Peter Paul Toth · 2007
  34. Aggressive Lipid-Lowering Therapy and Regression of Coronary Atheroma
    Uffe Ravnskov, Morley C. Sutter · 2004 · JAMA